Other Key Trials in the Treatment of BCG-Unresponsive High-Risk NMIBC

Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Three additional clinical trials will study nadofaragene firadenovec-vncg for the treatment of patients with non-muscle invasive bladder cancer.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.

Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.